Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Human leukocyte antigen susceptibility map for SARS-CoV-2

View ORCID ProfileAustin Nguyen, View ORCID ProfileJulianne K. David, View ORCID ProfileSean K. Maden, View ORCID ProfileMary A. Wood, View ORCID ProfileBenjamin R. Weeder, View ORCID ProfileAbhinav Nellore, View ORCID ProfileReid F. Thompson
doi: https://doi.org/10.1101/2020.03.22.20040600
Austin Nguyen
1Computational Biology Program; Oregon Health & Science University; Portland, OR, 97239; USA
2Department of Biomedical Engineering; Oregon Health & Science University; Portland, OR, 97239; USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Austin Nguyen
Julianne K. David
1Computational Biology Program; Oregon Health & Science University; Portland, OR, 97239; USA
2Department of Biomedical Engineering; Oregon Health & Science University; Portland, OR, 97239; USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Julianne K. David
Sean K. Maden
1Computational Biology Program; Oregon Health & Science University; Portland, OR, 97239; USA
2Department of Biomedical Engineering; Oregon Health & Science University; Portland, OR, 97239; USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sean K. Maden
Mary A. Wood
1Computational Biology Program; Oregon Health & Science University; Portland, OR, 97239; USA
3Portland VA Research Foundation; Portland, OR, 97239; USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mary A. Wood
Benjamin R. Weeder
1Computational Biology Program; Oregon Health & Science University; Portland, OR, 97239; USA
2Department of Biomedical Engineering; Oregon Health & Science University; Portland, OR, 97239; USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin R. Weeder
Abhinav Nellore
1Computational Biology Program; Oregon Health & Science University; Portland, OR, 97239; USA
2Department of Biomedical Engineering; Oregon Health & Science University; Portland, OR, 97239; USA
4Department of Surgery; Oregon Health & Science University; Portland, OR, 97239; USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Abhinav Nellore
  • For correspondence: nellore@ohsu.edu thompsre@ohsu.edu
Reid F. Thompson
1Computational Biology Program; Oregon Health & Science University; Portland, OR, 97239; USA
2Department of Biomedical Engineering; Oregon Health & Science University; Portland, OR, 97239; USA
5Department of Radiation Medicine; Oregon Health & Science University; Portland, OR, 97239; USA
6Department of Medical Informatics and Clinical Epidemiology; Oregon Health & Science University; Portland, OR, 97239; USA
7Division of Hospital and Specialty Medicine; VA Portland Healthcare System; Portland, OR, 97239; USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Reid F. Thompson
  • For correspondence: nellore@ohsu.edu thompsre@ohsu.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Genetic variability across the three major histocompatibility complex (MHC) class I genes (human leukocyte antigen [HLA] A, B, and C) may affect susceptibility to and severity of severe acute respiratory syndrome 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). We execute a comprehensive in silico analysis of viral peptide-MHC class I binding affinity across 145 HLA -A, -B, and -C genotypes for all SARS-CoV-2 peptides. We further explore the potential for cross-protective immunity conferred by prior exposure to four common human coronaviruses. The SARS-CoV-2 proteome is successfully sampled and presented by a diversity of HLA alleles. However, we found that HLA-B*46:01 had the fewest predicted binding peptides for SARS-CoV-2, suggesting individuals with this allele may be particularly vulnerable to COVID-19, as they were previously shown to be for SARS (1). Conversely, we found that HLA-B*15:03 showed the greatest capacity to present highly conserved SARS-CoV-2 peptides that are shared among common human coronaviruses, suggesting it could enable cross-protective T-cell based immunity. Finally, we report global distributions of HLA types with potential epidemiological ramifications in the setting of the current pandemic.

IMPORTANCE Individual genetic variation may help to explain different immune responses to a virus across a population. In particular, understanding how variation in HLA may affect the course of COVID-19 could help identify individuals at higher risk from the disease. HLA typing can be fast and inexpensive. Pairing HLA typing with COVID-19 testing where feasible could improve assessment of viral severity in the population. Following the development of a vaccine against SARS-CoV-2, the virus that causes COVID-19, individuals with high-risk HLA types could be prioritized for vaccination.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

RFT was supported by the U.S. Department of Veterans Affairs under award number 1IK2CX002049-01, and the Sunlin & Priscilla Chou Foundation.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data and code available at https://github.com/pdxgx/covid19. Raw sequence data available through https://www.ncbi.nlm.nih.gov/refseq/.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 15, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Human leukocyte antigen susceptibility map for SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Human leukocyte antigen susceptibility map for SARS-CoV-2
Austin Nguyen, Julianne K. David, Sean K. Maden, Mary A. Wood, Benjamin R. Weeder, Abhinav Nellore, Reid F. Thompson
medRxiv 2020.03.22.20040600; doi: https://doi.org/10.1101/2020.03.22.20040600
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Human leukocyte antigen susceptibility map for SARS-CoV-2
Austin Nguyen, Julianne K. David, Sean K. Maden, Mary A. Wood, Benjamin R. Weeder, Abhinav Nellore, Reid F. Thompson
medRxiv 2020.03.22.20040600; doi: https://doi.org/10.1101/2020.03.22.20040600

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (48)
  • Emergency Medicine (144)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4861)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (676)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (630)
  • Health Policy (321)
  • Health Systems and Quality Improvement (206)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5343)
  • Intensive Care and Critical Care Medicine (331)
  • Medical Education (93)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (686)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (208)
  • Oncology (440)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (781)
  • Public and Global Health (1817)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)